Clinical Trial Update: Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial results for sipuleucel-T (Provenge) in metastatic prostate cancer after hormone therapy have been reported, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PROVENGE (sipuleucel-T)

Snippet

Sponsor: Dendreon | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2010-09-06